GlaxoSmithKline Pharmaceuticals Q4 FY26 Results: PAT At ₹275 Crore, Board Recommends ₹57 Dividend
- By Kotak News Desk
- 14 May 2026 at 8:56 AM IST
- Market News
- 4m
Stay updated with the latest stock market developments and trends.
You can set Kotak Neo as a preferred source to receive regular market updates.
GSK India's revenue in FY26 was ₹3,790 crore and PAT was ₹1,012 crore. Q4 FY26 PAT stood at ₹275 crore. The company also recommended a final dividend of ₹57 per share.
GSK India reported continued profitable growth for FY26 despite disruptions in its supply chain that affected the availability of some products during the year. For the March quarter of FY26, revenue stood at ₹989 crore and profit after tax (PAT) came in at ₹275 crore, an increase of almost 6% from the same period last year. EBITDA margin improved by 90 basis points to 35%.
On 13 May 2026, GlaxoSmithKline Pharmaceuticals' share price dropped by 1.5% to close at ₹2,411.7 on the National Stock Exchange.
FY26 Performance In A Nutshell
The company posted full-year revenue of ₹3,790 crore, up 2% year-on-year (YoY), while PAT rose 10% YoY to ₹1,012 crore. EBITDA margin expanded by 290 basis points to 34%.
The company said growth was supported by pricing measures, investments in innovative therapies, better field force productivity, AI-led optimisation and disciplined cost management.
The company’s General Medicines portfolio delivered competitive performance during the quarter. Brands such as Augmentin, Calpol and T-Bact continued to maintain leadership positions in their categories. In the vaccines segment, Shingrix achieved strong traction as awareness around adult immunisation increased.
The oncology business also showed a strong growth momentum led by Jemperli and Zejula. During the year, Jemperli received first-line approval from Indian regulators for primary advanced and recurrent endometrial cancer, expanding the eligible patient base for the therapy.
GSK India also received marketing authorisation in India for Blenrep, an anti-BCMA therapy indicated for relapsed or refractory multiple myeloma in adults. The company said launch plans would be announced later.
Commenting on the results, Managing Director Bhushan Akshikar said the company is continuing its transition towards becoming an innovation-led organisation focused on high unmet medical needs through investments in high-growth therapy areas.
The board has recommended a final dividend of ₹57 per equity share for FY26.
Also Read - Stocks To Watch On 14 May 2026: Bharti Airtel, Tata Motors and More
Source:
Company Press Release
This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.
Kotak News Desk brings you latest updates, expert insights, and market-ready ideas - helping you stay informed and invest smarter.
Connect on: Linkedin
0 people liked this article.
